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Alopecia areata is regarded as a tissue-restricted auto-
immune disease of hair follicles in which follicular
activity is arrested because of the continued activity of
lymphocytic in¢ltrates. Actual loss of hair follicles does
not occur, even in hairless lesions. A variety of immu-
nomodulating therapies, including contact sensitizers
and immunomodulators, are part of the usual arma-
mentarium for this disorder. None of these treatments
have been consistent in their e⁄cacy, and many have
untoward side e¡ects. Nevertheless, their uses in valid
animal models provide a tool to dissect out molecular
mechanisms of therapeutic e¡ects. For several decades,
both mechlorethamine (for the treatment of cutaneous
T cell lymphoma) and anthralin (for the treatment of
psoriasis) have been used successfully.When these thera-
pies were tested in rat and mouse alopecia areata mod-
els, we found anthralin and mechlorethamine to be the
most e¡ective topical modalities, respectively. The un-
derlying cellular mechanisms may act through tar-
geting in¢ltrative lymphocytes, and the molecular
mechanisms may involve speci¢c cytokine expression
changes. These visible, accessible, and unilaterally trea-
ted animal model systems are ideal for studying novel
alopecia areata therapies, particularly in terms of their
in vivo molecular mechanisms of action. Keywords: an-
thralin/autoimmunity/cytokines/mechlorethamine. JID Sym-
posium Proceedings 8:212 ^216, 2003
Pathogenesis of alopecia areata Alopecia areata (AA) is a
common in£ammatory disease of the hair follicle, a¡ecting 1.7%
of the population, that can clinically present as patchy to
complete hair loss (Safavi et al, 1995); it is widely regarded as an
autoimmune disease (McDonagh and Messenger, 1996; McElwee
et al, 1999a; Randall, 2001). The pathogenic role of in¢ltrative T
lymphocytes has been directly demonstrated by cell transfer
experiments (McElwee et al, 1996, 1999c; Gilhar et al, 1998, 2001,
2002). These in¢ltrating T cells preferentially attack anagen hair
bulbs in the active lesions of AA (Perret et al., 1984; Todes-Taylor
et al, 1984). Loss of hair follicles does not actually occur even in
hairless lesions. Rather, in active AA the follicles no longer
produce visible hair ¢ber as a result of the continued activity
of the lymphocytic in¢ltrate. As with all other autoimmune
disorders, the cause of AA is multifactorial. Analysis of
family history suggests a genetic component for approximately
20% of cases, but to date there is no concrete evidence for
exactly which genes are responsible. A number of cytokines,
growth factors, and regulatory molecules have been post-
ulated as having signi¢cant roles in AA, including tumor
necrosis factor-a (TNF-a), interleukin-1b (IL-1b) and interferon-g
(IFN-g), IL-1 receptor (IL-1R), calcitonin gene^related protein
(CGRP), and other neuropeptides (Ho¡man et al, 1994; Cork
et al, 1995, 1996; Ho¡mann and Happle, 1995; Philpott et al, 1996;
Carroll et al, 1997).
Alopecia areata therapies Treatments for alopecia areata
include contact sensitizers, immunomodulators, and biological
response modi¢ers (Ho¡mann and Happle, 1996; Shapiro and
Price, 1998; Shapiro, 2002). Unfortunately, however, none of
these therapeutic modalities consistently produce successful
results and many have untoward side e¡ects. Topical anthralin
treatment (Nelson and Spielvogel, 1985; Fiedler-Weiss and Buys,
1987) and topical nitrogen mustard (Arrazola et al, 1985; Bernardo
et al, in press) are e¡ective on AA patients, but results have been
inconsistent. Exactly how these agents result in hair regrowth
and why only certain patients respond has not been elucidated.
Their successful application in a valid animal model would
provide a means to test the e⁄cacy and safety of therapeutic
reagents as well as dissect out their mechanism of action in
order to develop more targeted therapy with a more favorable
side-e¡ect pro¢le for AA patients.
Rodent models for alopecia areata Animal models provide
the means whereby new forms of treatment can be developed
and tested. There are two rodent models for AA. Aging C3H/
HeJ mice develop a nonscarring alopecia with clinical and
pathologic features similar to those of human AA (Sundberg
et al, 1994, 1996). The onset of hair loss is typically observed as
early as four months of age in females and six to twelve months
in males. Expression of hair loss rises to 20% in some colonies of
mice (Sundberg et al, 1994). The hair loss phenotype can be
reproduced by whole-skin grafting of the AA-a¡ected mouse
skin onto normal C3H/HeJ mice (McElwee et al, 1999b). The
other rodent model, the Dundee experimental bald rat (DEBR),
is a hooded rat strain that also exhibits hair loss lesions similar to
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those observed in human AA. All DEBR rats develop a normal
coat of hair from birth up to four months, but up to 30% of
males and 80% of females exhibit hair loss on their heads,
which then typically progresses to alopecia of the £anks and the
entire body (Michie et al, 1991; Zhang and Oliver, 1994).We and
other investigators have shown that various therapies can
stimulate hair regrowth in AA-a¡ected rats and mice (Oliver
and Lowe, 1995; McElwee et al, 1997; Freyschmidt-Paul et al, 1999,
2001; Shapiro et al, 1999; Tang et al, 2003a, b).
ANTHRALIN IN THE TREATMENT OFAA RODENTS
Anthralin is one of the oldest, most e¡ective, and widely used
therapeutic agents for the treatment of psoriasis (Wiegrebe and
Muller, 1995; Harris, 1998). It has now been shown to be successful
for some patients with patchyAA (Fiedler-Weiss and Buys, 1987).
Anthralin’s therapeutic e¡ects on AAwere tested on both rodent
AA models.
Anthralin therapy in AA-a¡ected C3H/HeJ mice A¡ected
C3H/HeJ mice were treated unilaterally daily for ¢ve days per
week on the dorsal skin with 0.2% anthralin ointment; the
contralateral side was treated with the vehicle alone. Signi¢cant
hair regrowth was observed on the treated side in 64% of the
mice (Tang et al, 2003a). Four mice displayed near complete
replacement of hairs of normal density and length. Hair
regrowth was observed unilaterally on the anthralin-treated side
as early as one week after the initiation of treatment in one
mouse. By week 10, there was extensive hair replacement with
normal hair density and quality on the anthralin-treated side in
the responding mice. The vehicle-treated side either remained
unchanged or continued to demonstrate hair loss compared to
baseline. The nonresponders showed either no hair regrowth as
compared to the control side or hair loss on both sides. In
anthralin-treated skin, local dermatitis with erythema and
hyperpigmentation was observed as early as two to three days
after starting treatment and continued for the duration of the
study.
Anthralin therapy in DEBR rats AA-a¡ected rats were
treated similarly on the dorsal surface, except with 0.1%
anthralin ointment. After six to eight weeks of treatment,
follicular activity was reversed with clear regrowth over nearly
all of the treated side in all rats whereas the control side
remained bald. Visible hair regrowth was observed as early as
one week after the onset of treatment in some rats.1 Among the
drugs tested on this AA model in our lab, topical anthralin
appears to be the most promising and exhibits near perfect hair
regrowth in all of the DEBR rats tested (Fig 1). The e¡ect of
anthralin on normalWistar rats after shaving was also tested. No
indication of its hair stimulatory e¡ects on normal rats was
observed after a similar course of treatment, indicating that
anthralin’s therapeutic e¡ects on hair regrowth are speci¢c to
AA-a¡ected rats.
Immunohistochemical studies in rats Immunohistochemical
analysis revealed that in¢ltrating lymphocytes in AA-a¡ected
DEBR rat skin were mainly composed of CD8þ cells along
with very few CD4þ cells. On the vehicle-treated side, CD8þ
cells were mainly present around the follicular periphery and also
penetrated the intrafollicular peribulbar area. In contrast, under
anthralin treatment the CD8þ cells were mainly interfollicular
and distributed more uniformly in the dermis. It appeared that
the distribution of these cells changed between the two sides
but that the absolute numbers did not (Tang et al, submitted).
Interestingly, the pattern of ICAM-1 (CD54 antibody) expres-
sion was very similar to that of CD8 and also showed consistent
redistribution in all rats tested (unpublished data). The number of
CD4þ cells in the tested rats was low, and there was no apprecia-
ble di¡erence between the two sides in either the number or the
location of the CD4þ cells.
Cytokines modulated by anthralin in AA-a¡ected
rodents In skin, a large number of cytokines are produced
under both normal and pathologic conditions, and they play
important roles in the pathogenesis of in£ammatory skin
diseases. The mechanism of anthralin’s therapeutic e¡ects in AA
is unclear. Various cytokines have been associated with the
success of anthralin in the treatment of psoriasis (Mrowietz et al,
1997; Chodorowska, 1998; Lange et al, 1998), and certain pro-
in£ammatory cytokines might be involved in the pathogenesis
of AA (Cork et al, 1995; Ho¡mann and Happle, 1995; Cork et al,
1996; Philpott et al, 1996; Carroll et al, 1997). To explore the
possible molecular mechanisms of anthralin’s therapeutic e¡ects
on hair restoration in AA-a¡ected C3H/HeJ mice and DEBR
rats, we performed RNase protection assays (RPA) and real-
time reverse transcription polymerase chain reactions (RT-PCR)
on the biopsies from anthralin-treated and vehicle-treated control
sides. In mice, RPA showed that the majority of the responding
mice displayed decreased expression of TNF-a andTNF-b on the
treated sides. In contrast, nonresponders remained unchanged in
the expression of TNF-a/b. Two abundantly expressed cytokines
(IL-18 and IL-1Ra) and other weakly expressed cytokines (IL-1a,
Figure1. A female DEBR rat was successfully treated unilaterally
with anthralin. The rat was treated on the left side with anthralin oint-
ment and on the right side with the vehicle for eight weeks.The treated side
showed near normal hair regrowth, whereas the left side remained alopecic.
1Tang L, Cao L, Lui H, Shapiro J: Restoration of follicular activity by anthralin in
DEBR rats a¡ected by alopecia areata. Exp Dermatol (submitted).
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IL-1b, IL-10, and IL-12) in mouse skin did not show any
signi¢cant di¡erences between the two sides (Table I).
The pattern of cytokine expression in DEBR rat skin after
anthralin treatment was di¡erent. IL-1a/b, IL-10, and IL-1Ra
were increased by the treatment in all the rats tested. TNF-b
mRNA was not consistently detected from the rat skin, and,
interestingly, TNF-a and IFN-g mRNAwere reduced (Table I).
Whether this di¡erential cytokine pro¢ling following anthralin
treatment is associated with the di¡erent responses between
the two animal models needs to be further investigated.
Alternatively, each rodent species may represent a di¡erent type
or subtype of AAwith di¡erent mechanisms involved.
MECHLORETHAMINE THERAPY IN AA-AFFECTED
C3H/HEJ MICE
Mechlorethamine was one of the ¢rst anticancer drugs devel-
oped, and it is still widely used in the treatment of lymphoma
(Engert et al, 1999;Tesch et al, 2001). Its topical formulation is reg-
ularly used to treat cutaneous T cell lymphoma (Ramsay et al,
1995; Duvic et al, 1996; Esteve et al, 1999). The low-dose topical
ointment has been shown to have some e⁄cacy with AA patients
(Arrazola et al, 1985; Bernardo et al, in press).We treated AA-af-
fected mice unilaterally on the dorsal skin with mechlorethamine
and, as a control, on the contralateral side with the vehicle oint-
ment. After ¢ve to ten weeks of therapy, a full pelage of hair cov-
ered the entire mechlorethamine-treated side in all the mice
whereas the vehicle-treated side showed either no change or con-
tinued hair loss (Fig 2). As a control, normal C3H/HeJ mice were
shaved on the back and then treated the same way as AA-a¡ected
mice. No di¡erence between mechlorethamine-treated and vehi-
cle-treated sides in hair regrowth was observed in the normal
mice after a similar course of treatment, indicating that mechlor-
ethamine’s therapeutic e¡ects on hair regrowth are speci¢c for
AA-a¡ected mice. For these mice, mechlorethamine appears to
be the most e¡ective treatment among the drugs tested to date
(Freyschmidt-Paul et al, 1999, 2001; Shapiro et al, 1999; Tang et al,
2003b).
Immunohistochemistry revealed that both CD4þ and
CD8þ lymphocytes were depleted by mechlorethamine treat-
ment whereas, on the vehicle-treated control sides, CD4þ and
CD8þ cells were easily observed in the peri- and intrafollicular
areas. In an in vitro test on activated primary mouse T lympho-
cytes, we found that humanT lymphocytes and cells from a lym-
phoma T cell line (Jurkat) were all much more susceptible to
mechlorethamine’s cytotoxic and proliferation inhibitory e¡ects
compared to all other native skin cells. These other skin cells
included follicular and epidermal keratinocytes in addition to
dermal and follicular dermal papillae ¢broblasts (Tang et al,
2003b). The data strongly suggest that topical mechlorethamine
therapy selectively targets the in¢ltrating lymphocytes in vivo in
AA-a¡ected skin to restore autoimmune-arrested hair follicle
activity.
Table I. Summary of cytokine expression mediated by anthralin and mechlorethamine in alopecia areata animal models. The
levels of di¡erent cytokines were normalized to that of L32 from the same sample. The ratio of treated over control was used to
determine the di¡erence in the gene expression between two sides. The ratio of greater than 2 or less than 0.5 was considered as




Animal: C3H/HeJ AA mouse
Therapy: Anthralin
Animal: C3H/HeJ AA Mouse
Therapy: Meclorethamine
IFN-g decreased not tested decreased
TNF-a decreased decreased decreased
TNF-b not tested decreased decreased
IL-1a increased no change no change
IL-1b increased no change no change
IL-1Ra increased no change no change
IL-10 increased not detected no change
IL-12 no change no change decreased
MIF-1 not tested not tested no change
IL-18 no change no change no change
: only decreased in the responding mice, no change in the non-responders.
Figure 2. A female C3H/HeJ mouse was successfully treated unilat-
erally with mechlorethamine. The mouse was treated with mechlor-
ethamine on the right side and with vehicle on the left side for eight
weeks. The right side was covered with full pelage of hair; left side re-
mained alopecic.
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As mentioned before, the cytokines IL-1b, TNF-a, IFN-g,
and IL-1Ra have been implicated in the pathogenesis of AA
(Ho¡mann and Happle, 1995; Cork et al, 1996; Philpott et al,
1996; Carroll et al, 1997). By comparing the cytokine expression
pro¢les between the mechlorethamine-treated and control sides,
we discovered that TNF-a/b, IL-12, and IFN-g were consistently
inhibited by mechlorethamine (Tang et al, 2003b). Other cyto-
kines, including IL-18, macrophage immigration factor-1
(MIF-1), and IL-1Ra, were abundantly expressed in mouse
skin but did not exhibit any di¡erences between the two sides.
These results con¢rm that mechlorethamine-treated C3H/HeJ
mice with an AA-like disease are a useful model in exploring
the comparative molecular mechanisms of topical therapeutic
agents for AA.
SUMMARY
No therapeutic modality consistently produces successful results
in AA, and all have untoward side e¡ects. How these reagents
result in hair regrowth is not clear. Successful use in a valid ani-
mal model would provide a tool to dissect out their mechanisms
of action in order to develop more targeted therapy with a milder
side-e¡ect pro¢le for patients with AA. Our ¢ndings illustrate
that AA-a¡ected DEBR rats and C3H/HeJ mice are excellent
models for studying therapy for AA and for exploring the corre-
sponding molecular mechanisms of action. Among all reagents
tested on these two rodent AA models, we found that anthralin
and mechlorethamine are the most e¡ective therapies.
At the cellular level, it appears that in¢ltrating lymphocytes are
targeted by various immunomodulating reagents.The pathogenic
roles of activated CD4þ and CD8þ lymphocytes have been
demonstrated in both human and animal models (Becker et al,
1996; McElwee et al, 1996, 1999c; Gilhar et al, 1998, 2001, 2002;
Bodemer et al, 2000). It is generally believed that CD8þ cells
are more crucial than CD4þ cells. This hypothesis is supported
by our data with anthralin and mechlorethamine in the rodent
models. Anthralin might modulate the immune reaction around
the hair follicles by redirecting the immune response away from
the antigen responsible for AA, thus restoring arrested hair folli-
cle activity. Mechlorethamine therapy might selectively target the
in¢ltrating lymphocytes in vivo in AA-a¡ected skin, as both
CD4þ and CD8þ lymphocytes are eliminated. This is further
supported by the di¡erential sensitivity to mechlorethamine’s cy-
totoxicity between lymphocytes and other skin and hair follicle
cells in vitro.
Molecular mechanisms responsible for hair follicle restoration
in AA are poorly understood. Altered expression of various cyto-
kines has been shown to be associated with the pathogenesis of
various autoimmune conditions, and some of them have served
as therapeutic target molecules (Cork et al, 1995; Joosten et al,
1996; Cope, 1998; Firestein, 1998; Feldmann and Maini, 2001; Kas-
siotis and Kollias, 2001).We compared cytokine expression pro-
¢les between AA-a¡ected and normal C3H/HeJ mouse and rat
skin, and found that TNF-a/b, IL-12, and IFN-g were more
abundantly expressed in AA-a¡ected rodents (data not shown).
It is not clear, however, whether decreased expression of TNF-
a/b, IL-12, and IFN-g is directly related to the restoration of the
autoimmune-arrested follicular activity in AA. The cytokine
pro¢les in the two rodent models according to di¡erent topical
treatments are summarized in Table I. Among all the cytokines
tested, TNF-a and IFN-g have been consistently modulated by
di¡erent therapies. It would be interesting to determine whether
any of them play a direct role in therapeutically induced hair re-
growth in AA-a¡ected animal models by using speci¢cally tar-
geted antibodies or anti-sense molecules.
Recently emerging transcripteomics and proteomics are a po-
tentially revolutionary breakthrough in determining the molecu-
lar mechanisms of disease and therapeutic actions. Our studies
have shown that topical anthralin and mechlorethamine are very
e¡ective in restoring the activity of autoimmune-induced arrest
of follicles in DEBR rats and C3H/HeJ mice, respectively. The
accessibility and visibility of skin and hair follicles provide con-
venience and accuracy in correlating therapeutic e⁄cacy to mole-
cular events. At molecular levels, genes responsible for follicular
activity and cutaneous immune function in AA patients should
be similar to those in AA-a¡ected DEBR rats and C3H/HeJ
mice. Studying the molecular mechanisms regulating follicular
activity in animal models would be of great bene¢t in the ra-
tional design of more re¢ned therapeutic modalities for AA
patients.
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